title: Progesterone receptor status in determining the prognosis of estrogen receptor positive/ HER2 negative breast carcinoma patients.
abstract: OBJECTIVE
  To evaluate the impact of progesterone receptor (PR) status on estrogen receptor (ER)-positive and HER2-negative breast cancer.
  
  
  METHODS
  A total of 1673 operable breast cancer patients, diagnosed from June 1984 to June 2011 were retrospectively reviewed and 400 patients with ER-positive and HER2-negative tumors were identified and evaluated. ER-positive and HER2-negative patients were classified into two groups: group A: ER+/PR-/HER2- and group B : ER+/PR+/HER2- according to PR status.
  
  
  RESULTS
  Median follow-up was 14.2 years (range 10.1-18.2). The ratio of postmenopausal patients was significantly higher in group A (68.2%, p=0.015). Grade 1 tumor and stage I disease were significantly higher in group B (15%, p=0.007 and 15%, p=0.005, respectively). Mean overall survival (OS) and disease free survival (DFS) were significantly better in group B (15.3±1.5 years vs 8.7±0.8 years, p=0.032; 10.5±1.6 years vs 5.7±0.5 years, p=0.022) as compared with group A. Relative risk for recurrence and death were two-fold higher in group A (p=0.05 and p=0.01, respectively).
  
  
  CONCLUSIONS
  PR status exerts a significant impact on prognosis of ER+/HER2- breast cancer.
authors.affiliation: Ankara Oncology Education and Research Hospital, Department of Medical Oncology, Ankara, Turkey.
authors.forename: Oznur
authors.initials: O
authors.lastname: Bal
authors.forename: Ulku
authors.initials: U
authors.lastname: Yalcintas Arslan
authors.forename: Ayse
authors.initials: A
authors.lastname: Durnali
authors.forename: Ummugul
authors.initials: U
authors.lastname: Uyetrk
authors.forename: Ayse
authors.initials: A
authors.lastname: Demirci
authors.forename: Didem
authors.initials: D
authors.lastname: Tastekin
authors.forename: Ahmet
authors.initials: A
authors.lastname: Ekinci
authors.forename: Onur
authors.initials: O
authors.lastname: Esbah
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Turker
authors.forename: Ozlem
authors.initials: O
authors.lastname: Uysal Sonmez
authors.forename: Berna
authors.initials: B
authors.lastname: Oksuzoglu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000737:chemistry* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D060787:Neoplasm Grading; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D016016:Proportional Hazards Models; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*; D011960:Receptors, Estrogen / Q000032:analysis*; D011980:Receptors, Progesterone / Q000032:analysis*; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C508053:ERBB2 protein, human